Hepatitis C Virus-related B Cell Subtypes in Non Hodgkin's Lymphoma

Overview

Journal World J Hepatol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2011 Nov 30

PMID 22125661

Citations 12

Authors

Adriano M Pellicelli

Massimo Marignani

Valerio Zoli

Mario Romano

Aldo Morrone

Lorenzo Nosotti

Giuseppe Barbaro

Antonio Picardi

Umberto Vespasiani Gentilucci

Daniele Remotti

Cecilia DAmbrosio

Caterina Furlan

Fabrizio Mecenate

Ettore Mazzoni

Ignazio Majolino

Roberto Villani

Arnaldo Andreoli

Giorgio Barbarini

Affiliations

Soon will be listed here.

Abstract

Aim: To evaluate if indolent B cell-non Hodgkin's lymphoma (B-NHL) and diffuse large B-cell lymphoma (DLBCL) in hepatitis C virus (HCV) positive patients could have different biological and clinical characteristics requiring different management strategies.

Methods: A group of 24 HCV related B-NHL patients (11 indolent, 13 DLBCL) in whom the biological and clinical characteristics were described and confronted. Patients with DLBCL were managed with the standard of care of treatment. Patients with indolent HCV-related B-NHL were managed with antiviral treatment pegylated interferon plus ribavirin and their course observed. The outcomes of the different approaches were compared.

Results: Patients with DLBCL had a shorter duration of HCV infection and a higher prevalence of HCV genotype 1 compared to patients with indolent B-NHL in which HCV genotype 2 was the more frequent genotype. Five of the 9 patients with indolent HCV-related B-NHL treated with only antiviral therapy, achieved a complete response of their onco-haematological disease (55%). Seven of the 13 DLBCL patients treated with immunochemotheraphy obtained a complete response (54%).

Conclusion: HCV genotypes and duration of HCV infection differed between B-NHL subtypes. Indolent lymphomas can be managed with antiviral treatment, while DLBCL is not affected by the HCV infection.

Citing Articles

Hepatitis C virus and non-Hodgkin's lymphomas: A minireview.

Khaled H, Abu-Taleb F, Haggag R J Adv Res. 2017; 8(2):131-137.

PMID: 28149648 PMC: 5272953. DOI: 10.1016/j.jare.2016.11.005.

Hepatitis C and double-hit B cell lymphoma successfully treated by antiviral therapy.

Galati G, Rampa L, Vespasiani-Gentilucci U, Marino M, Pisani F, Cota C World J Hepatol. 2016; 8(29):1244-1250.

PMID: 27803769 PMC: 5067444. DOI: 10.4254/wjh.v8.i29.1244.

Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma.

Merli M, Carli G, Arcaini L, Visco C World J Gastroenterol. 2016; 22(38):8447-8458.

PMID: 27784957 PMC: 5064026. DOI: 10.3748/wjg.v22.i38.8447.

Antiviral therapy improves overall survival in hepatitis C virus-infected patients who develop diffuse large B-cell lymphoma.

Hosry J, Mahale P, Turturro F, Miranda R, Economides M, Granwehr B Int J Cancer. 2016; 139(11):2519-28.

PMID: 27501007 PMC: 5028297. DOI: 10.1002/ijc.30372.

Hepatitis C virus-associated B-cell non-Hodgkin's lymphomas: what do we know?.

Vannata B, Arcaini L, Zucca E Ther Adv Hematol. 2016; 7(2):94-107.

PMID: 27054025 PMC: 4802504. DOI: 10.1177/2040620715623924.

References

Lister T, Crowther D, Sutcliffe S, Glatstein E, Canellos G, Young R . Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989; 7(11):1630-6. DOI: 10.1200/JCO.1989.7.11.1630. View

Prati D, Capelli C, Zanella A, Mozzi F, Bosoni P, Pappalettera M . Influence of different hepatitis C virus genotypes on the course of asymptomatic hepatitis C virus infection. Gastroenterology. 1996; 110(1):178-83. DOI: 10.1053/gast.1996.v110.pm8536854. View

Cocco P, Piras G, Monne M, Uras A, Gabbas A, G Ennas M . Risk of malignant lymphoma following viral hepatitis infection. Int J Hematol. 2008; 87(5):474-483. DOI: 10.1007/s12185-008-0086-3. View

Suarez F, Lortholary O, Hermine O, Lecuit M . Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood. 2006; 107(8):3034-44. DOI: 10.1182/blood-2005-09-3679. View

Quinn E, Chan C, Hadlock K, Foung S, Flint M, Levy S . The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis. Blood. 2001; 98(13):3745-9. DOI: 10.1182/blood.v98.13.3745. View

Marcucci F, Mele A . Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities. Blood. 2010; 117(6):1792-8. DOI: 10.1182/blood-2010-06-275818. View

Vallisa D, Bernuzzi P, Arcaini L, Sacchi S, Callea V, Marasca R . Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience. J Clin Oncol. 2005; 23(3):468-73. DOI: 10.1200/JCO.2005.06.008. View

de Sanjose S, Benavente Y, Vajdic C, Engels E, Morton L, Bracci P . Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol. 2008; 6(4):451-8. PMC: 3962672. DOI: 10.1016/j.cgh.2008.02.011. View

Gisbert J, Garcia-Buey L, Pajares J, Moreno-Otero R . Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: systematic review and meta-analysis. Gastroenterology. 2004; 125(6):1723-32. DOI: 10.1053/j.gastro.2003.09.025. View

10.

Schollkopf C, Smedby K, Hjalgrim H, Rostgaard K, Panum I, Vinner L . Hepatitis C infection and risk of malignant lymphoma. Int J Cancer. 2008; 122(8):1885-90. DOI: 10.1002/ijc.23416. View

11.

Mele A, Pulsoni A, Bianco E, Musto P, Szklo A, Sanpaolo M . Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood. 2003; 102(3):996-9. DOI: 10.1182/blood-2002-10-3230. View

12.

Vallisa D, Berte R, Rocca A, Civardi G, Giangregorio F, Ferrari B . Association between hepatitis C virus and non-Hodgkin's lymphoma, and effects of viral infection on histologic subtype and clinical course. Am J Med. 1999; 106(5):556-60. DOI: 10.1016/s0002-9343(99)00069-8. View

13.

Zignego A, Ferri C, Giannini C, Monti M, La Civita L, Careccia G . Hepatitis C virus genotype analysis in patients with type II mixed cryoglobulinemia. Ann Intern Med. 1996; 124(1 Pt 1):31-4. DOI: 10.7326/0003-4819-124-1_Part_1-199601010-00006. View

14.

Besson C, Canioni D, Lepage E, Pol S, Morel P, Lederlin P . Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs. J Clin Oncol. 2006; 24(6):953-60. DOI: 10.1200/JCO.2005.01.5016. View

15.

Zignego A, Ferri C, Giannelli F, Giannini C, Caini P, Monti M . Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas. Ann Intern Med. 2002; 137(7):571-80. DOI: 10.7326/0003-4819-137-7-200210010-00008. View

16.

Giordano T, Henderson L, Landgren O, Chiao E, Kramer J, El-Serag H . Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA. 2007; 297(18):2010-7. DOI: 10.1001/jama.297.18.2010. View

17.

Kobayashi M, Tanaka E, Sodeyama T, Urushihara A, Matsumoto A, Kiyosawa K . The natural course of chronic hepatitis C: a comparison between patients with genotypes 1 and 2 hepatitis C viruses. Hepatology. 1996; 23(4):695-9. DOI: 10.1053/jhep.1996.v23.pm0008666319. View

18.

Marignani M, Mangone M, Cox M, Angeletti S, Veggia B, Ferrari A . HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin's lymphoma treated with rituximab-containing regimens. Dig Liver Dis. 2010; 43(2):139-42. DOI: 10.1016/j.dld.2010.05.010. View

19.

Silvestri F, Pipan C, Barillari G, Zaja F, Fanin R, Infanti L . Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders. Blood. 1996; 87(10):4296-301. View

20.

Suarez F, Lefrere F, Besson C, Hermine O . Splenic lymphoma with villous lymphocytes, mixed cryoglobulinemia and HCV infection: deciphering the role of HCV in B-cell lymphomagenesis. Dig Liver Dis. 2007; 39 Suppl 1:S32-7. DOI: 10.1016/s1590-8658(07)80008-9. View